Bicara Therapeutics (BCAX) to Release Earnings on Tuesday

Bicara Therapeutics (NASDAQ:BCAX - Get Free Report) is projected to release its earnings data before the market opens on Tuesday, February 11th. Analysts expect Bicara Therapeutics to post earnings of ($0.31) per share for the quarter.

Bicara Therapeutics (NASDAQ:BCAX - Get Free Report) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($1.60) earnings per share for the quarter, missing analysts' consensus estimates of ($0.46) by ($1.14). On average, analysts expect Bicara Therapeutics to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Bicara Therapeutics Stock Down 3.7 %

NASDAQ BCAX traded down $0.47 on Friday, reaching $12.13. The stock had a trading volume of 253,436 shares, compared to its average volume of 366,845. The company's fifty day moving average price is $15.84. Bicara Therapeutics has a 12-month low of $11.10 and a 12-month high of $28.09.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on BCAX shares. Wedbush started coverage on Bicara Therapeutics in a research note on Thursday. They set an "outperform" rating and a $31.00 target price on the stock. Rodman & Renshaw began coverage on shares of Bicara Therapeutics in a research note on Tuesday, November 5th. They set a "buy" rating and a $48.00 price target on the stock. RODMAN&RENSHAW raised shares of Bicara Therapeutics to a "strong-buy" rating in a research note on Tuesday, November 5th. Finally, HC Wainwright upped their target price on shares of Bicara Therapeutics from $42.00 to $45.00 and gave the stock a "buy" rating in a research note on Monday, January 27th. Six equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Buy" and an average price target of $41.20.

About Bicara Therapeutics

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.